Universal molecular screening does not effectively detect Lynch syndrome in clinical practice

Background: Lynch syndrome (LS) due to an inherited damaging mutation in mismatch repair (MMR) genes comprises 3% of all incident colorectal cancer (CRC). Molecular testing using immunohistochemistry (IHC) for MMR proteins is a recommended screening tool to identify LS in incident CRC. This study as...

Full description

Bibliographic Details
Main Authors: Beatrice Brennan, Christine T. Hemmings, Ian Clark, Desmond Yip, Mitali Fadia, Douglas R. Taupin
Format: Article
Language:English
Published: SAGE Publishing 2017-04-01
Series:Therapeutic Advances in Gastroenterology
Online Access:https://doi.org/10.1177/1756283X17690990
_version_ 1819210369061617664
author Beatrice Brennan
Christine T. Hemmings
Ian Clark
Desmond Yip
Mitali Fadia
Douglas R. Taupin
author_facet Beatrice Brennan
Christine T. Hemmings
Ian Clark
Desmond Yip
Mitali Fadia
Douglas R. Taupin
author_sort Beatrice Brennan
collection DOAJ
description Background: Lynch syndrome (LS) due to an inherited damaging mutation in mismatch repair (MMR) genes comprises 3% of all incident colorectal cancer (CRC). Molecular testing using immunohistochemistry (IHC) for MMR proteins is a recommended screening tool to identify LS in incident CRC. This study assessed outcomes of population-based routine molecular screening for diagnosis of LS in a regional center. Methods: We conducted a prospective, consecutive case series study of universal IHC testing on cases of resected CRC from September 2004–December 2013. Referred cases with abnormal IHC results that attended a familial cancer clinic were assessed according to modified Bethesda criteria (until 2009) or molecular criteria (from 2009). Results: 1612 individuals underwent resection for CRC in the study period and had MMR testing by IHC. Of these, 274 cases (16.9%) exhibited loss of expression of MMR genes. The mean age at CRC diagnosis was 68.1 years (± standard deviation 12.7) and the mean age of those with an IHC abnormality was 71.6 (± 11.8). A total of 82 (29.9%) patients with an abnormal result were seen in a subspecialty familial cancer clinic. Patients aged under 50 ( p = 0.009) and those with loss of MSH6 staining ( p = 0.027) were more likely to be referred and to attend. After germ-line sequencing, 0.6% (10 of 82) were identified as having a clinically significant abnormality. A further eight probands with pathogenic germ-line mutations were identified from other referrals to the service over the same time period. Conclusions: While technically accurate, the yield of ‘universal’ IHC in detecting new Lynch probands is limited by real-world factors that reduce referrals and genetic testing. We propose an alternative approach for universal, incident case detection of Lynch syndrome with ‘one-stop’ MMR testing and sequencing.
first_indexed 2024-12-23T06:10:05Z
format Article
id doaj.art-4e80cc76a90f44fb8af334ff5eabdca1
institution Directory Open Access Journal
issn 1756-283X
1756-2848
language English
last_indexed 2024-12-23T06:10:05Z
publishDate 2017-04-01
publisher SAGE Publishing
record_format Article
series Therapeutic Advances in Gastroenterology
spelling doaj.art-4e80cc76a90f44fb8af334ff5eabdca12022-12-21T17:57:28ZengSAGE PublishingTherapeutic Advances in Gastroenterology1756-283X1756-28482017-04-011010.1177/1756283X17690990Universal molecular screening does not effectively detect Lynch syndrome in clinical practiceBeatrice BrennanChristine T. HemmingsIan ClarkDesmond YipMitali FadiaDouglas R. TaupinBackground: Lynch syndrome (LS) due to an inherited damaging mutation in mismatch repair (MMR) genes comprises 3% of all incident colorectal cancer (CRC). Molecular testing using immunohistochemistry (IHC) for MMR proteins is a recommended screening tool to identify LS in incident CRC. This study assessed outcomes of population-based routine molecular screening for diagnosis of LS in a regional center. Methods: We conducted a prospective, consecutive case series study of universal IHC testing on cases of resected CRC from September 2004–December 2013. Referred cases with abnormal IHC results that attended a familial cancer clinic were assessed according to modified Bethesda criteria (until 2009) or molecular criteria (from 2009). Results: 1612 individuals underwent resection for CRC in the study period and had MMR testing by IHC. Of these, 274 cases (16.9%) exhibited loss of expression of MMR genes. The mean age at CRC diagnosis was 68.1 years (± standard deviation 12.7) and the mean age of those with an IHC abnormality was 71.6 (± 11.8). A total of 82 (29.9%) patients with an abnormal result were seen in a subspecialty familial cancer clinic. Patients aged under 50 ( p = 0.009) and those with loss of MSH6 staining ( p = 0.027) were more likely to be referred and to attend. After germ-line sequencing, 0.6% (10 of 82) were identified as having a clinically significant abnormality. A further eight probands with pathogenic germ-line mutations were identified from other referrals to the service over the same time period. Conclusions: While technically accurate, the yield of ‘universal’ IHC in detecting new Lynch probands is limited by real-world factors that reduce referrals and genetic testing. We propose an alternative approach for universal, incident case detection of Lynch syndrome with ‘one-stop’ MMR testing and sequencing.https://doi.org/10.1177/1756283X17690990
spellingShingle Beatrice Brennan
Christine T. Hemmings
Ian Clark
Desmond Yip
Mitali Fadia
Douglas R. Taupin
Universal molecular screening does not effectively detect Lynch syndrome in clinical practice
Therapeutic Advances in Gastroenterology
title Universal molecular screening does not effectively detect Lynch syndrome in clinical practice
title_full Universal molecular screening does not effectively detect Lynch syndrome in clinical practice
title_fullStr Universal molecular screening does not effectively detect Lynch syndrome in clinical practice
title_full_unstemmed Universal molecular screening does not effectively detect Lynch syndrome in clinical practice
title_short Universal molecular screening does not effectively detect Lynch syndrome in clinical practice
title_sort universal molecular screening does not effectively detect lynch syndrome in clinical practice
url https://doi.org/10.1177/1756283X17690990
work_keys_str_mv AT beatricebrennan universalmolecularscreeningdoesnoteffectivelydetectlynchsyndromeinclinicalpractice
AT christinethemmings universalmolecularscreeningdoesnoteffectivelydetectlynchsyndromeinclinicalpractice
AT ianclark universalmolecularscreeningdoesnoteffectivelydetectlynchsyndromeinclinicalpractice
AT desmondyip universalmolecularscreeningdoesnoteffectivelydetectlynchsyndromeinclinicalpractice
AT mitalifadia universalmolecularscreeningdoesnoteffectivelydetectlynchsyndromeinclinicalpractice
AT douglasrtaupin universalmolecularscreeningdoesnoteffectivelydetectlynchsyndromeinclinicalpractice